Moderna wins patent lawsuit against BioNTech/Pfizer
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Canaccord Genuity analyst William Maughan maintained a Buy rating and increased the price target from $171 to $171.44 on Nov. 27, 2024. This analyst has an accuracy rate of 71%. JP Morgan analyst ...
Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...
BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an ...
BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...
Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...
Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results